DOCSLIB.ORG

Biochemical Mechanism Studies of Venlafaxine by Metabonomic Method in Rat Model of Depression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biochemical Mechanism Studies of Venlafaxine by Metabonomic Method in Rat Model of Depression European Review for Medical and Pharmacological Sciences 2013; 17: 41-48 Biochemical mechanism studies of venlafaxine by metabonomic method in rat model of depression S. FENLI*, W. FENG, Z. RONGHUA, L. HUANDE Clinical Pharmacy & Pharmacology Research Institute, Second Xiangya Hospital, Central South University, Changsha, P.R. China *Department of Pharmacy, First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, P.R. China Abstract. – BACKGROUND: Venlafaxine is a mitters’ metabolism and coordinate the bal- new antidepressant that has a chemical struc- ance of 5-HT, NE and DA to reach the anti-de- ture and neuropharmacologic profile distinct pressed function. from those of existing antidepressants. The studies about the mechanism of pharmacologi- Key Words: cal action of venlafaxine mostly investigated the Venlafaxine, Depression model, Neurotransmitter, effects of venlafaxine on 5-hydroxytryptamine Metabonomics (5-HT), norepinephrine (NE) and dopamine (DA) levels, while only few studies examined the ef- fects on the metabolites levels and ratio of these monoamines neurotransmitters. AIM: To study the biochemical mechanism of venlafaxine through determining the metabo- Introduction lism of monoamine neurotransmitters in brain tissues of rat model of depression after admin- Venlafaxine is a new antidepressant that has a istration of venlafaxine using metabonomic chemical structure and neuropharmacologic pro- method. file distinct from those of existing antidepres- MATERIALS AND METHODS: The rat model sants, including tricyclic antidepressants (TCAs), of depression was established by using the meth- ods of separation and chronic unpredictable selective serotonin reuptake inhibitors (SSRIs), stress. We have determined 5-HT, NE, DA and and monoamine oxidase inhibitors. The neuro- their metabolites, i.e., 5-hydroxyindole-3-acetic chemical characteristics of venlafaxine include acid (5-HIAA), 4-hydroxy-3-methoxyphenylglycol inhibition of serotonin (5-hydroxytryptamine, 5- (MHPG) sulfate, 3,4-dihydroxyphenylacetic acid HT) and norepinephrine (NE) synaptosomal re- (DOPAC) and homovanillic acid (HVA) in rat uptake and a somewhat weaker inhibition of brain tissues by liquid chromatography-electro- spray ionization tandem mass spectrometry (LC- dopamine (DA) reuptake in vitro. It is the first in- ESI-MS/MS) following chronic administration of hibitor that inhibits the reuptake of both 5-HT different venlafaxine doses (8, 16, 32 mg·kg-1) and NE (SNRIs). Because of its unique pharma- and saline solution for 14 days. Linear discrimi- cological properties, venlafaxine provides posi- nant analysis (LDA) and principal components tive clinical efficacy that is comparable or superi- analysis (PCA) were used in data analysis of or to that of TCAs and SSRIs but has a side ef- metabonomic. fect profile resembling that of SSRIs. It has be- RESULTS: Compared with saline, venlafaxine could significantly increase brain 5-HT and NE come a first-line drug for the treatment of major levels at middle dose (16 mg·kg-1) or high dose depressive disorders and obtained more and more (32 mg·kg-1), especially at middle dose. These in- attention1-2. creases were greater than those seen with the So far, the studies about the mechanism of comparable dose of selective serotonin reuptake pharmacological action of venlafaxine mostly inhibitor (SSRI), fluoxetine, under the same ex- investigated the acute or chronic effects of ven- perimental conditions. CONCLUSIONS: Venlafaxine lowers brain lafaxine on 5-HT, NE and DA levels in rat brain neurotransmitter metabolite levels by decreas- in vivo. A single administration dose of ven- ing brain neurotransmitters turnover. Venlafax- lafaxine (1, 4 and 8 mg·kg-1, i.p.) produced an ine could correct the disorder of neurotrans- increase in extracellular levels of 5-HT and NE Corresponding Author: Li Huande, MD; e-mail: [email protected] 41 S. Fenli, W. Feng, Z. Ronghua, L. Huande at 8 mg·kg-1 3. Another study reported that there levels of 5-HIAA, 5-HT, MHPG, HVA, and was a significant increase in extracellular NE DOPAC were examined in 14 never-hospitalized and 5-HT concentrations with no increase in DA outpatients with unipolar depression. It found extracellular concentrations in the hippocampus that 9 of 14 patients showed a significant de- of rats after an acute dose of 20 mg·kg-1 (i.p.) crease (42%) in their CSF 5-HIAA concentra- venlafaxine4. Acute administration of venlafax- tions after at least 6 weeks treatment with ven- ine (3-50 mg·kg-1) produced a significant dose- lafaxine, but no change in other CSF measures. dependent increase in extracellular NE in the In the present study, we used metabonomic frontal cortex following s.c. injection reaching a method to study the biochemical mechanism of maximum value at 50 mg·kg-1. Conversely, these venlafaxine through determining the change of increases in NE were not paralleled by 5-HT, the metabolism of 5-HT, NE, DA in brain tissues which showed no increase in extracellular con- of rat model of depression after administration of centrations at doses up to and including 505 venlafaxine, and try to find out the mechanism of mg·kg-1. While, one study6 demonstrated that the pharmacological action of venlafaxine from the effects of acute i.p. administration of various metabolic profile of biomarkers. doses (5-20 mg·kg-1) of venlafaxine on extracel- lular 5-HT levels in frontal cortex and hip- pocampus were dose-dependent and chronic Materials and Methods venlafaxine (5 mg·kg-1, i.p. daily for 4 weeks) did not elevate basal 5-HT levels in either cortex Test Animals and Model Preparation or hippocampus. Millan et al.7 showed that ven- 60 male albino Sprague-Dawley rats (body lafaxine could elevate extracellular 5-HT and weigh 170~200 g) were purchased from the Ani- NE levels in the frontal cortex of freely moving mal Department of Second Xiangya Hospital rats at a low dose (0.63 mg·kg-1, s.c.), and ele- (Changsha, China). Animals were divided into nor- vate DA levels at 2.5 mg·kg-1. In the nucleus ac- mal control group (group I), model group (group cumbens and striatum, venlafaxine provoked a II), low dose of venlafaxine group (group III), mid- pronounced increase in dialysis levels of 5-HT, dle dose of venlafaxine group (group IV), high whereas DA levels were only marginally affect- dose of venlafaxine group (group V) and fluoxe- ed at 10 mg·kg-1. A comparable pattern of data tine group (group VI) with 10 rats in each group by was obtained for venlafaxine: the influence of its randomized block design according to the results acute administration upon 5-HT, NE, and DA of Open-field test. All rats were housed under con- levels in frontal cortex was not significantly stant temperature environment (20~22°C) with a modified by chronic administration of venlafax- regular 12 h light/dark cycle and were free access ine for 2 weeks. Another previous study8 showed to food drinking water (except accepting stress in that venlafaxine (10 mg·kg-1, i.p.) increased the the depression model preparation). efflux of 5-HT, NE and DA levels in the pre- According to references12-13, normal control frontal cortex. The levels of 5-HT increased to group rats were raised in two cages (5 per cage) 310%, an effect approximately twice the effect and not given any stress, while isolated-living on NE in the hippocampus. Venlafaxine also condition and chronic mild unpredictable stress produced a moderate increase in DA levels in (CUMS) were given to the other 5 groups rats to the prefrontal cortex but had no effect in the hip- set up depression model. 21-day stress exposure pocampus. paradigm, which involved relatively harsh stres- However, the effects of venlafaxine on the sors, including immobilization (3 h), swimming metabolites levels and ratio of these monoamines in cold water (4°C, 5 min), restricted food access neurotransmitters have not yet been examined in (24 h), restricted water access (24 h), clamp tail the above experiments which were done in nor- (1 min), alterations of the light-dark cycle (24 h), mal animals. In fact, the metabolism change can weave (160 Hz, 5 min), hot environment (45°C, also affect the levels of monoamines neurotrans- 5 min), twice feet-electric shock (36 V, 10 s per mitters. 5-hydroxyindole-3-acetic acid (5-HIAA), time). Following such exposure, animals exhibit- 4-hydroxy-3-methoxyphenylglycol (MHPG), 3, ed a persistent reduction in responsiveness to 4-dihydroxyphenylacetic acid (DOPAC) and ho- pleasurable stimuli, measured by a decrease in movanillic acid (HVA) are the main acidic their consumption of a 1 percent sucrose solu- metabolites of 5-HT, NE and DA, respectively9-10. tion. In addition, a number of behavioral changes Only in one study11, cerebrospinal fluid (CSF) were seen in these animals which were assessed 42 Biochemical mechanism studies of venlafaxine by metabonomic method in rat model of depression with Open-field test. There were 56 model rats ly, and rats of other groups were still in isolated- used in the experiment at last because 4 rats died living conditions. Rats in group I and II were in the process of model preparation. treated by saline and rats in group III, IV, V, VI The procedures used in this study were carried were treated with low, middle, high dose (8, 16, out according to the Chinese Guidelines on Ani- 32 mg·kg-1) of venlafaxine and fluoxetine (2 mals experimentation (State Science and Tech- mg·kg-1), respectively. All drugs were dissolved nology Commission, #2, November 14, 1988) in saline and were intragastric administrated dai- and were approved by the Ethics Committee of ly for 2 weeks. On the morning of the 15th day, the Second Xiangya Hospital of Central South all rats were decapitated simultaneously and the University. whole brain was separated out quickly on ice, and then thrown into liquid nitrogen immediate- Test Drugs and Reagents ly.
Load more

Recommended publications
  • Does the Antidepressant-Like Effect of Mirtazapine and Venlafaxine Differ Between Male and Female Rats?
    ORIGINAL ARTICLE Volume 43, Issue 1, January-February 2020 doi: 10.17711/SM.0185-3325.2020.002 Does the antidepressant-like effect of mirtazapine and venlafaxine differ between male and female rats? Adriana Álvarez Silva,1 Alonso Fernández-Guasti1 1 Departamento de Farmacobiología, ABSTRACT Centro de Investigación y de Estu- dios Avanzados del Instituto Politécni- Depression is a global health problem with nearly 350 million people affected, mainly women. co Nacional, Ciudad de México, Introduction. México. However, nowadays a rising amount of men are being diagnosed. This makes necessary the screening of new treatment options that are effective in women as well as in men. Objective. To analyze if the administration of Correspondence: mirtazapine and venlafaxine to male and female rats shows a sex-related antidepressant-like effect, and the Alonso Fernández-Guasti Laboratorio de Farmacología possible associated neurochemical mechanisms. Method. Mirtazapine (40 mg/kg) or venlafaxine (60 mg/kg) Conductual, Centro de Investigación were administered subchronically to young adult male and female (ovariectomized and steroid-primed) rats, y de Estudios Avanzados del Instituto and their antidepressant-like effects were evaluated using the forced swim test (FST). The active behaviors, Politécnico Nacional. swimming and climbing, were also analyzed. a) mirtazapine and venlafaxine reduced immobility Calzada de los Tenorios 235, Results. Col Granjas Coapa, in the FST in males and females; b) both antidepressants increased climbing and swimming in male rats; Alcaldía Tlalpan, c) in female rats, mirtazapine and venlafaxine only increased swimming. Discussion and conclusion. In 14330, Ciudad de México, México. males, the effects of mirtazapine and venlafaxine seem to be produced by the activation of the serotonergic Phone: +52 (55) 5483 - 2848 and noradrenergic systems.
    [Show full text]
  • Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors Marisa Rosenberg Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2715 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ANTINOCICEPTIVE EFFECTS OF MONOAMINE REUPTAKE INHIBITORS IN ASSAYS OF PAIN-STIMULATED AND PAIN-DEPRESSED BEHAVIOR A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University By Marisa B. Rosenberg Bachelor of Science, Temple University, 2008 Advisor: Sidney Stevens Negus, Ph.D. Professor, Department of Pharmacology/Toxicology Virginia Commonwealth University Richmond, VA May, 2012 Acknowledgement First and foremost, I’d like to thank my advisor Dr. Steven Negus, whose unwavering support, guidance and patience throughout my graduate career has helped me become the scientist I am today. His dedication to education, learning and the scientific process has instilled in me a quest for knowledge that I will continue to pursue in life. His thoroughness, attention to detail and understanding of pharmacology has been exemplary to a young person like me just starting out in the field of science. I’d also like to thank all of my committee members (Drs.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed Et Al
    US0078.93053B2 (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed et al. (45) Date of Patent: Feb. 22, 2011 (54) TREATING PSYCHOLOGICAL CONDITIONS WO WO 2006/127418 11, 2006 USING MUSCARINIC RECEPTORM ANTAGONSTS (75) Inventors: Brian Seed, Boston, MA (US); Jordan OTHER PUBLICATIONS Mechanic, Sunnyvale, CA (US) Chau et al. (Nucleus accumbens muscarinic receptors in the control of behavioral depression : Antidepressant-like effects of local M1 (73) Assignee: Theracos, Inc., Sunnyvale, CA (US) antagonist in the porSolt Swim test Neuroscience vol. 104, No. 3, pp. 791-798, 2001).* (*) Notice: Subject to any disclaimer, the term of this Lind et al. (Muscarinic acetylcholine receptor antagonists inhibit patent is extended or adjusted under 35 chick Scleral chondrocytes Investigative Ophthalmology & Visual U.S.C. 154(b) by 726 days. Science, vol.39, 2217-2231.* Chau D., et al., “Nucleus Accumbens Muscarinic Receptors in the (21) Appl. No.: 11/763,145 Control of Behavioral Depression: Antidepressant-like Effects of Local M1 Antagonists in the Porsolt Swin Test.” Neuroscience, vol. (22) Filed: Jun. 14, 2007 104, No. 3, Jun. 14, 2001, pp. 791-798. Bechtel, W.D., et al., “Biochemical pharmacology of pirenzepine. (65) Prior Publication Data Similarities with tricyclic antidepressants in antimuscarinic effects only.” Arzneimittelforschung, vol. 36(5), pp. 793-796 (May 1986). US 2007/O293480 A1 Dec. 20, 2007 Chau, D.T. et al., “Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local Related U.S. Application Data Mantagonist in the Porsolt Swim test.” Neuroscience, vol. 104(3), (60) Provisional application No.
    [Show full text]
  • Review Article Monoamine Reuptake Inhibitors in Parkinson's Disease
    Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review
    [Show full text]
  • 5-HT2A Receptors in the Central Nervous System the Receptors
    The Receptors Bruno P. Guiard Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System The Receptors Volume 32 Series Editor Giuseppe Di Giovanni Department of Physiology & Biochemistry Faculty of Medicine and Surgery University of Malta Msida, Malta The Receptors book Series, founded in the 1980’s, is a broad-based and well- respected series on all aspects of receptor neurophysiology. The series presents published volumes that comprehensively review neural receptors for a specific hormone or neurotransmitter by invited leading specialists. Particular attention is paid to in-depth studies of receptors’ role in health and neuropathological processes. Recent volumes in the series cover chemical, physical, modeling, biological, pharmacological, anatomical aspects and drug discovery regarding different receptors. All books in this series have, with a rigorous editing, a strong reference value and provide essential up-to-date resources for neuroscience researchers, lecturers, students and pharmaceutical research. More information about this series at http://www.springer.com/series/7668 Bruno P. Guiard • Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System Editors Bruno P. Guiard Giuseppe Di Giovanni Faculté de Pharmacie Department of Physiology Université Paris Sud and Biochemistry Université Paris-Saclay University of Malta Chatenay-Malabry, France Msida MSD, Malta Centre de Recherches sur la Cognition Animale (CRCA) Centre de Biologie Intégrative (CBI) Université de Toulouse; CNRS, UPS Toulouse, France The Receptors ISBN 978-3-319-70472-2 ISBN 978-3-319-70474-6 (eBook) https://doi.org/10.1007/978-3-319-70474-6 Library of Congress Control Number: 2017964095 © Springer International Publishing AG 2018 This work is subject to copyright.
    [Show full text]
  • Long-Term Administration of Citalopram Reduces Basal and Stress-Induced Extracellular Noradrenaline Levels in Rat Brain
    Psychopharmacology (2007) 194:73–81 DOI 10.1007/s00213-007-0826-8 ORIGINAL INVESTIGATION Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain Yukie Kawahara & Hiroshi Kawahara & Fumi Kaneko & Masatoshi Tanaka Received: 24 December 2006 /Accepted: 7 May 2007 /Published online: 30 May 2007 # Springer-Verlag 2007 Abstract suppressed only in the LC. The effect of local application of Rationale Panic disorders are commonly treated with clonidine was enhanced only in the BLA. selective serotonin reuptake inhibitors (SSRIs). However, Conclusion The present results indicate that chronic ad- the effect of SSRIs on noradrenaline systems in the brain ministration of citalopram strongly decreases the extracel- has not been fully elucidated at the present time. lular levels of noradrenaline in the brain. The anti-panic Objectives The effects of long-term administration of effect of citalopram might be due to sensitization of the α2- citalopram, an SSRI, on basal as well as stress-induced adrenoceptors leading to suppression of the stress response extracellular noradrenaline levels in the basolateral nucleus through noradrenergic activity. This mechanism is specific of the amygdala (BLA) and the locus coeruleus (LC) were for the BLA. determined. In addition, the responsiveness of noradren- aline transporters and α2-adrenoceptors were determined Keywords Citalopram . Microdialysis . Amygdala . after long-term administration of citalopram. Basolateral . Rat . Noradrenaline . Chronic treatment
    [Show full text]
  • Evaluation of Antidepressant Activity of Granisetron in Albino Mice
    Int. J. Pharm. Sci. Rev. Res., 27(2), July – August 2014; Article No. 59, Pages: 345-348 ISSN 0976 – 044X Research Article Evaluation of Antidepressant Activity of Granisetron in Albino Mice Sathisha Aithal1*, Geetha S2, Swetha ES2, Balaji V2, Chethan Kumar S3 1Associate Professor,2Post graduate, Department of Pharmacology, S.S. Institute of Medical Sciences and Research Centre, Davangere.3Research Coordinator, S.S. Institute of Medical Sciences and Research Centre, Davangere, Karnataka, India. *Corresponding author’s E-mail: [email protected] Accepted on: 14-06-2014; Finalized on: 31-07-2014. ABSTRACT Depression is one of the highly prevalent and disabling conditions associated with significant morbidity and mortality. The present study was performed to evaluate the antidepressant activity of granisetron, a 5-HT3 receptor antagonist in rodent models of depression such as forced swim test (FST) and tail suspension test (TST). Freshly prepared solution of granisetron (0.5mg/kg) were administered orally to mice for 14 days, and the experiments were conducted on day 1 and day 14. There was a statistically significant (P <0.05) reduction in the duration of immobility in FST on both acute (day 01) and chronic (day 14) treatment with granisetron compared to control as well as amitriptyline treated groups. However, in TST there was significant reduction in immobility in animals treated with granisetron compared to the control group only. Hence, the present study showed that graniosetron has antidepressant like action, which may be because of its antagonism at the 5-HT3 receptor site and that it may be used as an alternative for the treatment of depression.
    [Show full text]
  • Does the Antidepressant-Like Effect of Mirtazapine and Venlafaxine Differ Between Male and Female Rats? Salud Mental, Vol
    Salud mental ISSN: 0185-3325 ISSN: 0186-761X Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Álvarez Silva, Adriana; Fernández-Guasti, Alonso Does the antidepressant-like effect of mirtazapine and venlafaxine differ between male and female rats? Salud mental, vol. 43, no. 1, 2020, January-February, pp. 3-9 Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz DOI: 10.17711/SM.0185-3325.2020.002 Available in: http://www.redalyc.org/articulo.oa?id=58262790002 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative ORIGINAL ARTICLE Volume 43, Issue 1, January-February 2020 doi: 10.17711/SM.0185-3325.2020.002 Does the antidepressant-like effect of mirtazapine and venlafaxine differ between male and female rats? Adriana Álvarez Silva,1 Alonso Fernández-Guasti1 1 Departamento de Farmacobiología, ABSTRACT Centro de Investigación y de Estu- dios Avanzados del Instituto Politécni- Depression is a global health problem with nearly 350 million people affected, mainly women. co Nacional, Ciudad de México, Introduction. México. However, nowadays a rising amount of men are being diagnosed. This makes necessary the screening of new treatment options that are effective in women as well as in men. Objective. To analyze if the administration of Correspondence: mirtazapine and venlafaxine to male and female rats shows a sex-related antidepressant-like effect, and the Alonso Fernández-Guasti Laboratorio de Farmacología possible associated neurochemical mechanisms.
    [Show full text]
  • The Combination of Mirtazapine Plus Venlafaxine Reduces Immobility In
    Pharmacology, Biochemistry and Behavior 187 (2019) 172817 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior T ⁎ Adriana Alvarez Silva, Alonso Fernández-Guasti Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, México City, México. ARTICLE INFO ABSTRACT Keywords: Introduction: Depression is a psychiatric disorder with higher incidence in women. Among the most common and Mirtazapine less investigated adverse effects of antidepressants are the female sexual dysfunctions. Up to one third of the Venlafaxine patients fail to respond to antidepressants; therefore, more treatment alternatives are necessary. The combina- Forced swim test tion of mirtazapine plus venlafaxine, known as “California Rocket Fuel” has shown to be an option for treatment- Lordosis resistant depression. However, there are no reports of the effects of this combination in animal models and its Proceptivity action on female sexual behavior is unknown. Aim: To analyze the effect of mirtazapine and venlafaxine alone or combined –given at doses with actions on the forced swim test- on female rat sexual behavior. Methods: Mirtazapine (10, 20 or 40 mg/kg) and venlafaxine (15, 30 or 60 mg/kg) or their combinations (2.5/ 3.75, 5/7.5, 10/15 and 20/30 mg/kg mirtazapine and venlafaxine, respectively) were injected to sexually re- ceptive female rats. We evaluated their effect on the forced swim test (FST). The doses that reduced immobility were tested on proceptivity and receptivity.
    [Show full text]
  • The Effect of Fluoxetine on Anxiety-Related Behaviours During Development
    The effect of fluoxetine on anxiety-related behaviours during development Diana Chan A thesis in fulfilment of the requirements for the degrees of Doctor of Philosophy/Master of Psychology (Clinical) School of Psychology The University of New South Wales i Thesis/Dissertation Sheet Surname/Family Name : Chan Given Name/s : Diana Abbreviation for degree as give in the University calendar : PhD/M. Psych (Clinical) Faculty : Science School : Psychology Thesis Title : The effect of fluoxetine on anxiety-related behaviours during development Abstract 350 words maximum: (PLEASE TYPE) Selective serotonin reuptake inhibitors (SSRIs) are amongst the most commonly prescribed medications, and there is substantial evidence that they ameliorate symptoms of anxiety and depression. However, much of this research has been conducted in adults, and comparatively little is known about their risks and effectiveness at other ages. The experiments reported in this thesis contribute to addressing this knowledge gap by examining the effects of developmental exposure to fluoxetine (i.e., Prozac), which is one of the most frequently prescribed SSRIs, using a rat model. A significant number of infants are exposed to this drug during gestation or in the early postnatal period as up to 10% of mothers are prescribed SSRIs perinatally, and previous studies show that these drugs cross the placental barrier and are found in breast milk. The experiments described in Chapter 2 failed to find any consistent effects of early-life exposure to fluoxetine on the development of learned fear. Another set of experiments focused on adolescence, which is a peak period for the development of anxiety disorders. Critically, previous research has shown that adolescents are impaired at extinction, which forms the basis of exposure therapy, the gold-standard treatment for aberrant fear and worry.
    [Show full text]
  • Preclinical Pharmacology of F-98214-TA, a Novel Potent Serotonin and Norepinephrine Uptake Inhibitor with Antidepressant and Anxiolytic Properties
    Psychopharmacology (2005) 182: 400–413 DOI 10.1007/s00213-005-0087-3 ORIGINAL INVESTIGATION Inés Artaiz . Arturo Zazpe . Ana Innerárity . Elena del Olmo . Alvaro Díaz . José Angel Ruiz-Ortega . Elena Castro . Ruth Pena . Luis Labeaga . Angel Pazos . Aurelio Orjales Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties Received: 14 February 2005 / Accepted: 31 May 2005 / Published online: 21 July 2005 # Springer-Verlag 2005 Abstract Rationale: Serotonin (5-HT) and norepineph- the immobility in the forced swimming test in mice and rats rine (NE) re-uptake inhibitors (SNRIs) have been proposed (30 mg/kg, p.o.). Chronic administration of F-98214-TA − − to have a higher efficacy and/or faster onset of action (14 days, 30 mg kg 1 day 1, p.o.) attenuated the hyperac- than previously available antidepressants. Objectives: We tivity induced by olfactory bulbectomy in rats, confirm- examined in biochemical, electrophysiological and behav- ing its antidepressant-like properties. Interestingly, the ioural assays the antidepressant properties of (S)-(−)-4-[(3- same dosage regimen significantly increased the social fluorophenoxy)-phenyl]methyl-piperidine (F-98214-TA), a interaction time in rats, suggesting an additional poten- compound that displays very high affinity for 5-HT and NE tial anxiolytic activity. In most assays the compound was transporters. Results: F-98214-TA potently inhibited the more potent than fluoxetine, venlafaxine and desipramine. uptake of both 5-HT and NE into rat brain synaptosomes Conclusions: F-98214-TA is a novel SNRI that displays (IC50=1.9 and 11.2 nM, respectively) and decreased the greater potency than other reference antidepressants in electrical activity of dorsal raphe serotonergic neurones animal models predictive of antidepressant and anxiolytic (ED50=530.3 μg/kg i.v.), an effect completely abolished by activities.
    [Show full text]
  • Effect of YM992, a Novel Antidepressant With
    Jpn. J. Pharmacol. 90, 197 – 200 (2002) Short Communication Effect of YM992, a Novel Antidepressant With Selective Serotonin Re-uptake Inhibitory and 5-HT2A Receptor Antagonistic Activity, on a Marble-Burying Behavior Test as an Obsessive-Compulsive Disorder Model Hiromi Takeuchi*, Shin-ichi Yatsugi and Tokio Yamaguchi Neuroscience Research, Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan Received March 4, 2002 Accepted August 2, 2002 ABSTRACT—YM992 ((S)-2-[[(7-fluoroindan-4-yl)oxy]methyl]morpholine) monohydrochloride is a novel antidepressant with selective serotonin (5-hydroxytryptamine, 5-HT) re-uptake inhibition and 5-HT2A recep- tor antagonistic activity. The effects of YM992 and two selective 5-HT re-uptake inhibitors (SSRIs) were studied in a marble-burying behavior test as a model of an obsessive-compulsive disorder (OCD) in mice at doses of 5, 10 and 15 mg/kg, i.p. YM992 and fluoxetine significantly inhibited marble-burying behavior at a dose of 15 mg/kg (i.p.) without affecting spontaneous locomotor activities. Citalopram also significantly inhibited the behavior at doses of 5, 10 and 15 mg/kg (i.p.) without affecting spontaneous locomotor acti- vities. These results suggest that YM992, as well as SSRIs, may exhibit anti-OCD activity in addition to an antidepressive effect in clinical use. Keywords: YM992, Obsessive-compulsive disorder, Marble-burying behavior test Obsessive-compulsive disorder (OCD) is characterized havior test. The marble-burying behavior test is suggested by repeated, persistent and dysphoric thoughts (obsessions), to be a useful model for evaluating anti-OCD drugs (6).
    [Show full text]